These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An evaluation of leucocyte adherence inhibition microassay using colorectal cancer cell lines.
    Author: Machida S, Yamauchi M, Sato M, Ishioka T, Takashima K, Nishikawa T, Fukushima M, Koie H.
    Journal: Gan; 1980 Jun; 71(3):387-92. PubMed ID: 6998824.
    Abstract:
    The leucocyte adherence inhibition (LAI) microassay using crude extracts from colorectal cancer cell lines (M-7609 and S-7512) was evaluated as a test of immunological antitumor reactivity in colorectal cancer patients. The optimal antigen concentration for differentiating cancer patients from control subjects was 0.05 mg/ml protein. The cut-off values of LAI index for determining reactive and nonreactive cases was -0.20. The numbers of colorectal cancer patients reactive against antigens M (derived from M-7609), S (derived from S-7512) and M + S were 9 of 19, 9 of 12 of 18, respectively, whereas against control antigens K (derived from K-7610, pulmonary cancer), SF (derived from cultured fibroblastic cells) and T (derived from fresh colorectal cancer tissue), they were only 1 of 18, 1 of 17, and 3 of 15, respectively. The mean LA indices of the Dukes A and B group, and of the Dukes C and recurrent cancer group were -0.28 and -0.24, but that of a tumor-free postoperative group, another malignant disease group and a group of healthy individuals were -0.04, -0.05, and -0.03, respectively. Judging from these results, LAI microassay using cultured human cancer cell lines as tumor antigen sources is suitable as a test for evaluating the antitumor immunmoreactivity of colorectal cancer patients.
    [Abstract] [Full Text] [Related] [New Search]